A leading contributor of science and knowledge through discoveries.
Currently Not Accepting Students.
Graduate students at MSc and PhD levels
Professor and Canada Research Chair in chromatin dynamics
Dr. Jim Davie received his B.Sc. and Ph.D. degrees from the University of British Columbia. His post-doctoral training was with Dr. Ken van Holde at Oregon State University. Dr. Davie is presently a Professor in the Department of Biochemistry and Medical Genetics at the University of Manitoba. He serves on several Editorial Boards of journals publishing in Biochemistry, Cell Biology and Molecular Biology and is Editor of the journal Biochemistry and Cell Biology. He has served as Chair and panel member on Peer Review Committees. He directs the Manitoba Next Generation DNA Sequencing platform, which provides state-of-the-art genomic DNA sequencing to Manitoba researchers. His research interests include epigenetic regulation of gene expression in normal and diseased cells, signal transduction pathways, and biomarkers in the detection of disease. He holds a Canada Research Chair in Chromatin Dynamics. In 2015, he was inducted as a Fellow into the Canadian Academy of Health Sciences and the Royal Society of Canada.
Dr. Davie’s research interests include epigenetic regulation of gene expression in normal and diseased cells. His research program explores the role of chromatin modifiers in regulating gene expression. His early work reported that butyrate was a histone deacetylase inhibitor which arrested cancer cell proliferation. Recent research from his lab reported that histone deacetylases act from RNA to catalyze dynamic acetylation of histones bound to transcribed genes. His current research program explores the mechanisms by which histone modifications associated with the transcribed genes body communicate with proteins associate with RNA to regulate pre-mRNA splicing. Dr. Davie’s lab is also interested in working out the mechanisms by which signals (mitogens) received at the cell surface are transmitted into the nucleus via a signal transduction pathway, called the RAS-mitogen activated protein kinase pathway, to turn on specific genes (immediate early genes). His recent endeavours explore the role of DNA methylation in diseases such as fetal alcohol spectrum disorder and type 2 diabetes.
Manitoba Epigenetics Network site